Skip to main content

Advertisement

Table 2 Age correlation with DAT activity, measured with FP-CIT SPECT and FE-PE2I PET

From: Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT—a clinical comparison

  HC, n = 28 PS, n = 22
All R All p Female/male R All R All p Low DAT/normal DAT R
Caudate
 FP-CIT, SUR − 0.496 0.007 − 0.599*/− 0.360 − 0.354 0.107 − 0.565*/− 0.396
 FE-PE2I, BPND − 0.577 0.001 − 0.803**/− 0.402 −0.569 0.006 − 0.679**/− 0.965**
 FE-PE2I, SUVR − 0.502 0.007 − 0.796**/− 0.295 − 0.546 0.009 − 0.649**/− 0.970**
Putamen
 FP-CIT, SUR − 0.400 0.035 − 0.543/− 0.161 − 0.207 0.355 − 0.612**/− 0.544
 FE-PE2I, BPND − 0.540 0.003 − 0.697**/− 0.395 − 0.153 0.497 − 0.475 /− 0.564
 FE-PE2I, SUVR − 0.430 0.022 − 0.556*/− 0.287 − 0.150 0.505 − 0.433 /− 0.698
Striatum
 FP-CIT, SUR − 0.449 0.016 − 0.567*/− 0.280 − 0.267 0.230 − 0.602*/− 0.496
 FE-PE2I, BPND − 0.588 0.001 − 0.780**/− 0.424 − 0.328 0.136 − 0.610**/− 0.832
 FE-PE2I, SUVR − 0.480 0.010 − 0.675*/− 0.302 − 0.316 0.153 − 0.568*/− 0.916*
SN
 FE-PE2I, BPND 0.071 0.719 0.246 /− 0.117 − 0.175 0.436 − 0.333 /− 0.221
 FE-PE2I, SUVR 0.058 0.768 0.199/− 0.460 − 0.152 0.500 − 0.273 /− 0.139
  1. Correlations are calculated for mean DAT availability values in the respective compartments (averaged between the left and right hemispheres). Patients with low DAT n = 17, patients with normal DAT n = 5
  2. SUR specific uptake ratio, BPND binding potential relative to non-displaceable binding, SUVR specific uptake value ratio, SN substantia nigra, HC healthy controls, PS parkinsonian syndrome
  3. *Correlation is significant at the 0.05 level (two-tailed)
  4. **Correlation is significant at the 0.01 level (two-tailed)
  5. Correlation is not significant (two-tailed)